Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion
Open Access
- 9 October 2023
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (1) , 215-223
Abstract
Aims: To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double‐blind crossover study. Materials and Methods: Thirty‐two adults with type 1 diabetes on continuous subcutaneous insulin infusion participated in two periods: each period included hyperglycaemia induced by a missed mealtime bolus (day 1) and by suspension of basal insulin delivery (day 2). When hyperglycaemia [plasma glucose (PG) >240 mg/dl] occurred, a correction bolus of URLi or Humalog was given and time to hyperglycaemia recovery (PG = 140 mg/dl), pharmacokinetics and glucodynamics were compared. Results: Following a missed mealtime bolus, URLi significantly reduced maximum PG (−13 mg/dl; p = .02), and produced numerically more rapid decline in PG (23 mg/dl/h; p = .07), and faster recovery from hyperglycaemia (−23 min; p = .1) versus Humalog, although differences were not significant. Following basal suspension, URLi significantly reduced maximum PG (−6 mg/dl; p = .02), and produced faster PG decline (24 mg/dl/h; p < .001) and faster recovery from hyperglycaemia (−16 min; p < .01) vs. Humalog. Following a correction bolus of URLi, accelerated insulin lispro absorption was observed versus Humalog: early 50% t max was reduced by 6 or 12 min, and AUC0‐15min was increased 2.5‐ or 4.3‐fold after correction boluses by subcutaneous infusion (day 1) or injection (day 2), respectively (all p < .001). Conclusions: During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection.Keywords
Funding Information
- Eli Lilly and Company
This publication has 21 references indexed in Scilit:
- Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014Diabetes Therapy, 2017
- The rise of technology in diabetes care. Not all that is new is necessarily betterPediatric Diabetes, 2016
- Insulin Analogs—Are They Worth It? Yes!Diabetes Care, 2014
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010Diabetes Care, 2013
- Ultrafast-Acting Insulins: State of the ArtJournal of Diabetes Science and Technology, 2012
- Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitusCochrane Database of Systematic Reviews, 2010
- Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysisDiabetologia, 2008
- Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients1The Journal of Clinical Endocrinology & Metabolism, 1999
- Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.Diabetes, 1999
- Comparison of Human Regular and Lispro Insulins After Interruption of Continuous Subcutaneous Insulin Infusion and in the Treatment of Acutely Decompensated IDDMDiabetes Care, 1998